Circulating Tumor Cell-Based Patient-Derived Xenograft Models of Metastatic Bladder Cancer as a Platform for Development of Novel Therapeutic Approaches
Abstract
A lack of progress in the treatment of advanced bladder cancer stems from, at least in part, from a lack of model systems which recapitulate the evolution of the disease in the context of treatment. In order to address this limitation, we have developed a cohort of patient-derived xenograft (PDX) models derived from circulating tumor cells (CTC) obtained from the peripheral blood of patients with metastatic bladder cancer. Importantly, we have developed paired models from patients derived from CTC samples obtained prior to initiating, and at the time of disease progression on, cisplatin-based chemotherapy. We have performed RNA sequencing of these models to probe mechanisms of cisplatin-resistance identifying multiple pathways associated with cisplatin-resistance. Current work is focused on functional validation of these pathways in an attempt to identify novel therapeutic strategies to prevent/overcome cisplatin-resistance.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2018
- Accession Number
- AD1056811
Entities
People
- Matthew D. Galsky
Organizations
- Icahn School of Medicine at Mount Sinai